Analysts are rooting for hospital stocks. Here’s why
Rising incomes, healthcare needs and higher health insurance penetration have led to a promising demand outlook for hospital stocks, which are poised for sustained growth, analysts believe.
Overweight on India! Goldman Sachs sees domestic market as major source of creating multibaggers
Goldman Sachs is optimistic about India's medium-term growth prospects and recommends foreign investors build exposure in the emerging market due to its stable macroeconomics and strong historical track record. The bank favours domestic cyclicals, especially banks and investment cyclicals such as industrials and cement. It also expects themes like "make in India" and quality at a reasonable price to play out in the coming years. The bank has identified largecap compounders and midcap multibaggers as stocks investors should consider for increasing exposure in the medium term. India's aggregate equity market capitalization has surged 12-fold since 2003.
As bull run on D-Street continues, here are top 10 ideas for next 3-4 weeks
This week, 18,650-18,700 is expected to be a crucial hurdle and, if the index decisively surpasses this area, then 18,800-19,000 levels can't be ruled out
Hot Stocks | Bet on Apollo Hospitals Enterprises, HUDCO for short term
The entire Healthcare space has been buzzing and seems to be finding its mojo back. Along with pharmaceutical companies, ‘Apollo Hospitals’ too performed well throughout this week.
Buy Apollo Hospitals Enterprise; target of Rs 5300: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Apollo Hospitals Enterprise has recommended buy rating on the stock with a target price of Rs 5300 in its research report dated June 01, 2023.
Buy Apollo Hospitals; target of Rs 5450: Motilal Oswal
Motilal Oswal is bullish on Apollo Hospitals recommended buy rating on the stock with a target price of Rs 5450 in its research report dated May 31, 2023.
Auto should be one of the outperforming sectors in the near term: Sandip Sabharwal
Obviously, given the way most commodities have stabilised and also fallen so drastically, you will see many of the consumer names also do well. And as far as I think you were talking about the auto sales numbers, I think they have been pretty decent. So I think most of the frontline auto companies look pretty well placed. So I guess that should be one of the outperforming sectors.
It reported revenues of ₹6,705 crore and loss of ₹304 crore in FY23. While the offline pharmacy distribution business generated earnings before interest, tax, depreciation and amortisation (Ebitda) of ₹534 crore in FY23, growing 31% year-on-year (YoY), the digital health business has been burning cash on an average to the tune of ₹180 crore per quarter.
So I think midcap and small cap stocks are likely to see the positive momentum. And in heavyweights selective counter from FMCG, auto, banks, defence would likely to see the positive setup. While index may stuck in a range where declines could be bought with support of 18400-18442 marks.
Apollo Hospitals gains 4% on growth plan, brokerages also positive
Most brokerages have a 'buy' call for Apollo Hospitals, seemingly impressed with the company's strong growth plan and aim to bring down losses at Apollo Health Co
Hot Stocks: Brokerage view on Apollo Hospitals, Prestige Estates, Bharti Airtel and City Union Bank
Global brokerage firms have maintained their ratings on Apollo Hospitals, Prestige Estates and Bharti Airtel, while City Union Bank has been downgraded to Neutral. Jefferies has a buy rating on Apollo Hospitals and Prestige Estates, with target prices of Rs 5300 and Rs 560 respectively. Meanwhile, CLSA has maintained a buy rating on Bharti Airtel, with a target price of Rs 140. Macquarie has downgraded City Union Bank to Neutral, with a target price of Rs 140, citing weaker growth and ROA inconsistencies.
Apollo Hospitals' occupancy to reach 70%, Apollo 24*7 on path to breakeven: MD
Apollo Hospitals will reach its occupancy target by reducing its reliance on institutional patients and increasing focus on international patients, recruitment of more doctors and improving the payor mix.
Looking forward to outstanding performance from offline pharmacy: Suneeta Reddy, Apollo Hospitals
Yes, by the fourth quarter, we will be EBITDA neutral and I think that we are working towards that. Most of our expenditure has already been incurred and as the revenues pick up, we will be EBITDA neutral.